Linkage of Calprotectin with Inflammation, Activity and Treatment Response of Rheumatoid Arthritis: A Meta-Analysis

References

• Weyand CM , GoronzyJJ. The immunology of rheumatoid arthritis. Nat. Immunol.22(1), 10–18 (2021).
   PubMed Web of Science ®Google Scholar
• Tanaka Y . Rheumatoid arthritis. Inflamm. Regen.40, 20 (2020).
   PubMed Web of Science ®Google Scholar
• van der Woude D , vander Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol.32(2), 174–187 (2018).
   PubMed Web of Science ®Google Scholar
• Singh N , LiCI. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. Curr. Opin. Rheumatol.33(3), 292–299 (2021).
   PubMed Web of Science ®Google Scholar
• Camean-Castillo M , Gimeno-BallesterV, Rios-SanchezE, Fenix-CaballeroS, Vazquez-RealM, Alegre-DelRey E. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. J. Clin. Pharm. Ther.44(3), 384–396 (2019).
   PubMed Web of Science ®Google Scholar
• Romano C , EspositoS, FerraraR, CuomoG. Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin. Biol. Ther.21(5), 661–674 (2021).
   PubMed Web of Science ®Google Scholar
• Atzeni F , TalottaR, MasalaIF, BongiovanniS, BoccassiniL, Sarzi-PuttiniP. Biomarkers in rheumatoid arthritis. Isr Med. Assoc. J.19(8), 512–516 (2017).
   PubMed Web of Science ®Google Scholar
• Wei JC , LeongPY, LiuGY. Chaperone/scaffolding/adaptor protein 14-3-3eta (eta): a diagnostic marker of rheumatoid arthritis. Int. J. Rheum. Dis.23(11), 1439–1442 (2020).
   PubMed Web of Science ®Google Scholar
• Mori A , MitsuyamaK, SakemiRet al. Evaluation of serum calprotectin levels in patients with inflammatory bowel disease. Kurume Med. J.66(4), 209–215 (2021).
   PubMedGoogle Scholar
• Romand X , PacletMH, CourtierAet al. Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: results from the DESIR cohort. Joint Bone Spine88(1), 105068 (2021).
   PubMed Web of Science ®Google Scholar
• Torgutalp M , YaylaME, ErogluDSet al. Serum calprotectin is indicating clinical and ultrasonographic disease activity in rheumatoid arthritis, even with normal C-reactive protein levels. Mediterr. J. Rheumatol.32(1), 56–65 (2021).
   PubMedGoogle Scholar
• Jarlborg M , CourvoisierDS, LamacchiaCet al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res. Ther.22(1), 105 (2020).
   PubMed Web of Science ®Google Scholar
• Nordal HH , FagerholMK, HalseAK, HammerHB. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand. J. Clin. Lab. Invest.78(1–2), 102–108 (2018).
   PubMed Web of Science ®Google Scholar
• Hurnakova J , HulejovaH, ZavadaJet al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: a large cohort study. PLOS ONE12(8), e0183420 (2017).
   PubMed Web of Science ®Google Scholar
• Tweehuysen L , den BroederN, van HerwaardenNet al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open4(1), e000654 (2018).
   PubMed Web of Science ®Google Scholar
• Choi IY , GerlagDM, HereniusMJet al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann. Rheum. Dis.74(3), 499–505 (2015).
   PubMed Web of Science ®Google Scholar
• Hutton B , SalantiG, CaldwellDMet al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med.162(11), 777–784 (2015).
   PubMed Web of Science ®Google Scholar
• Wang Y , LiangY. Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. Int. J. Clin. Exp. Pathol.12(3), 1009–1014 (2019).
   PubMed Web of Science ®Google Scholar
• Van Hoovels L , Vander CruyssenB, BogaertL, Vanden Bremt S, BossuytX. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis. Clin. Chem. Lab. Med.58(1), 40–49 (2019).
   PubMed Web of Science ®Google Scholar
• Hurnakova J , HulejovaH, ZavadaJet al. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clin. Rheumatol.37(8), 2055–2062 (2018).
   PubMed Web of Science ®Google Scholar
• Nielsen UB , BruhnLV, EllingsenT, Stengaard-PedersenK, HornungN. Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate. Scand. J. Clin. Lab. Invest.78(1–2), 62–67 (2018).
   PubMed Web of Science ®Google Scholar
• Jonsson MK , SundlisaeterNP, NordalHHet al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann. Rheum. Dis.76(12), 2031–2037 (2017).
   PubMed Web of Science ®Google Scholar
• Nordal HH , BrokstadKA, SolheimM, HalseAK, KvienTK, HammerHB. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res. Ther.19(1), 3 (2017).
   PubMedGoogle Scholar
• Mansour HE , AbdullrhmanMA, MobasherSAet al. Serum calprotectin in rheumatoid arthritis: a promising diagnostic marker, how far is it related to activity and sonographic findings? J. Med. Ultrasound 25(1), 40–46 (2017).
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J , Victoria HernandezM, Ruiz-EsquideVet al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res. (Hoboken)68(7), 899–906 (2016).
   PubMed Web of Science ®Google Scholar
• Patro PS , SinghA, MisraR, AggarwalA. Myeloid-related protein 8/14 levels in rheumatoid arthritis: marker of disease activity and response to methotrexate. J. Rheumatol.43(4), 731–737 (2016).
   PubMed Web of Science ®Google Scholar
• Nordal HH , BrunJG, HordvikM, EidsheimM, JonssonR, HalseAK. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. Scand. J. Rheumatol.45(4), 274–281 (2016).
   PubMed Web of Science ®Google Scholar
• Acar A , GuzelS, SarifakiogluBet al. Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment. Clin. Rheumatol.35(11), 2685–2692 (2016).
   PubMed Web of Science ®Google Scholar
• Hurnakova J , ZavadaJ, HanovaPet al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res. Ther.17, 252 (2015).
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J , Ruiz-EsquideV, HernandezMVet al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford)54(12), 2239–2243 (2015).
   PubMed Web of Science ®Google Scholar
• Garcia-Arias M , Pascual-SalcedoD, RamiroSet al. Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Mol. Diagn. Ther.17(1), 49–56 (2013).
   PubMed Web of Science ®Google Scholar
• Andres Cerezo L , MannH, PechaOet al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res. Ther.13(4), R122 (2011).
   PubMed Web of Science ®Google Scholar
• Hammer HB , HaavardsholmEA, KvienTK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand. J. Rheumatol.37(3), 179–182 (2008).
   PubMed Web of Science ®Google Scholar
• de Seny D , FilletM, RibbensCet al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin. Chem.54(6), 1066–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Hammer HB , OdegardS, FagerholMKet al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann. Rheum. Dis.66(8), 1093–1097 (2007).
   PubMed Web of Science ®Google Scholar
• Sunahori K , YamamuraM, YamanaJet al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res. Ther.8(3), R69 (2006).
   PubMed Web of Science ®Google Scholar
• De Rycke L , BaetenD, FoellDet al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol.206(1), 17–27 (2005).
   PubMed Web of Science ®Google Scholar
• Drynda S , RingelB, KekowMet al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol. Res. Pract.200(2), 165–171 (2004).
   PubMed Web of Science ®Google Scholar
• Madland TM , HordvikM, HagaHJ, JonssonR, BrunJG. Leukocyte protein calprotectin and outcome in rheumatoid arthritis. A longitudinal study. Scand. J. Rheumatol.31(6), 351–354 (2002).
   PubMed Web of Science ®Google Scholar
• Berntzen HB , MuntheE, FagerholMK. The major leukocyte protein L1 as an indicator of inflammatory joint disease. Scand. J. Rheumatol. Suppl.76, 251–256 (1988).
   PubMedGoogle Scholar
• Brun JG , HagaHJ, BoeEet al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J. Rheumatol.19(6), 859–862 (1992).
   PubMed Web of Science ®Google Scholar
• Berntzen HB , FagerholMK, OstensenM, MowinckelP, HoyeraalHM. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J. Rheumatol.18(1), 133–138 (1991).
   PubMed Web of Science ®Google Scholar
• Haga HJ , BrunJG, BerntzenHB, CerveraR, KhamashtaM, HughesGR. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus2(1), 47–50 (1993).
   PubMed Web of Science ®Google Scholar
• Carlsen K , MalhamM, HansenLFet al. Serum calprotectin in adolescents with inflammatory bowel disease-a pilot investigation. J. Pediatr. Gastroenterol. Nutr.68(5), 669–675 (2019).
   PubMed Web of Science ®Google Scholar
• Hu H , DuF, ZhangS, ZhangW. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod. Rheumatol.29(5), 836–842 (2019).
   PubMed Web of Science ®Google Scholar
• Kessel C , HolzingerD, FoellD. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin. Immunol.147(3), 229–241 (2013).
   PubMed Web of Science ®Google Scholar
• van den Bosch MH , BlomAB, SchelbergenRFet al. Alarmin S100A9 induces proinflammatory and catabolic effects predominantly in the M1 macrophages of human osteoarthritic synovium. J. Rheumatol.43(10), 1874–1884 (2016).
   PubMed Web of Science ®Google Scholar
• Sakellariou G , LombardiG, VitoloBet al. Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study. Clin. Exp. Rheumatol.37(3), 429–436 (2019).
   PubMed Web of Science ®Google Scholar